Agenus Showcases BOT+BAL Data Across Three ESMO 2026 Studies
LEXINGTON, Mass., July 17, 2026 Agenus Inc. announced that three investigator-sponsored studies evaluating its investigational botensilimab plus balstilimab (BOT+BAL)...
AGEO Study
Advertisement
Advertisement
